Q-omics provides the consensus-scored NWD2 profile across patient tissues and cancer cell-line models. NWD2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, NWD2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NWD2 RNA expression shows 13,258 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, COAD, and GBM as cancer lineages where NWD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NWD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NWD2 survival associations across molecular data types. NWD2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NWD2 RNA expression–survival associations across cancer types. High NWD2 expression shows unfavorable associations in STAD, ACC, UVM and KIRP, but favorable associations in BRCA and LGG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for NWD2 RNA expression.
This table summarizes NWD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NWD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NWD2 shows lower tumor expression in COAD, THCA, READ and BRCA and higher tumor expression in LUSC and LIHC. The COAD box plot shows higher NWD2 RNA expression in normal versus tumor tissue (log2 FC = −0.562, t-test p < 0.001).
This table shows molecular features associated with NWD2 in patient tissues and cancer cell lines. In patient samples, NWD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NWD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
